SK Biopharm, Research and Development Organization Reorganized 'Centered on Process'

Promotion of Jo Hyeongrae to Head of Communications Headquarters

SK Biopharm is reorganizing its research and development (R&D) organization from a treatment approach-centered structure to a process-centered structure focusing on technology analysis and preclinical stages.

SK Biopharm announced on the 5th that it has carried out next year's organizational restructuring and executive appointments following a report to the board of directors.

First, to rapidly secure the next-generation new drug pipeline, the existing R&D organization, which was divided by modality (treatment approach), will be reorganized into a process-centered organization focusing on technology sourcing and analysis, internal project incubation, and preclinical stages. Through this, it is expected that various ongoing projects both inside and outside the company can be advanced with greater speed.

Additionally, to strengthen the commercial (enterprise product) function, which is a core part of the company-wide focus on OI (Operation Improvement), a Commercial Division has been newly established to unify sales and distribution, thereby accelerating the sales growth of the epilepsy treatment 'Xcopri' in the United States.

Furthermore, to enhance external credibility through strengthened communication with the market and stakeholders, Director Cho Hyung-rae, who had been leading and acting as interim head of the existing Global Communications Division, has been promoted to Head of Communications.

SK Biopharm stated, "Through this personnel appointment, we plan to establish a foundation for sustainable growth and further strengthen our competitiveness in the global market."

This content was produced with the assistance of AI translation services.